Literature DB >> 10194057

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis.

W J Burman1, K Gallicano, C Peloquin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10194057     DOI： 10.1086/515174

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  40 in total

1.  Drug Interactions with Antiretrovirals.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

Review 2.  The challenge of new drug discovery for tuberculosis.

Authors:  Anil Koul; Eric Arnoult; Nacer Lounis; Jerome Guillemont; Koen Andries
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

3.  In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.

Authors:  Karin Seifert; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 4.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  HIV and tuberculosis coinfection: inextricably linked liaison.

Authors:  Vincent Idemyor
Journal:  J Natl Med Assoc       Date:  2007-12       Impact factor: 1.798

Review 6.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

7.  Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study.

Authors:  Kathrin Zürcher; Marie Ballif; Lukas Fenner; Sonia Borrell; Peter M Keller; Joachim Gnokoro; Olivier Marcy; Marcel Yotebieng; Lameck Diero; E Jane Carter; Neesha Rockwood; Robert J Wilkinson; Helen Cox; Nicholas Ezati; Alash'le G Abimiku; Jimena Collantes; Anchalee Avihingsanon; Kamon Kawkitinarong; Miriam Reinhard; Rico Hömke; Robin Huebner; Sebastien Gagneux; Erik C Böttger; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2019-02-08       Impact factor: 25.071

8.  Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.

Authors:  R E Polk; D F Brophy; D S Israel; R Patron; B M Sadler; G E Chittick; W T Symonds; Y Lou; D Kristoff; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

9.  Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients.

Authors:  E Ribera; L Pou; A Fernandez-Sola; F Campos; R M Lopez; I Ocaña; I Ruiz; A Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers.

Authors:  Christophe Schmitt; Myriam Riek; Katie Winters; Malte Schutz; Susan Grange
Journal:  Arch Drug Inf       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.